Editas Medicine (EDIT) Cash & Equivalents (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash & Equivalents data on file, last reported at $146.6 million in Q4 2025.

• Quarterly Cash & Equivalents rose 11.48% year-over-year to $146.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.6 million (up 11.48% YoY) and the FY2025 annual result came in at $146.6 million, up 11.48% from the prior year.
• Cash & Equivalents retreated to $146.6 million in Q4 2025 per EDIT's latest filing, from $165.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $354.9 million in Q1 2021 and bottomed at $64.4 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $144.1 million (2022), against an average of $169.8 million.
• The widest annual swing landed in 2024, when Cash & Equivalents sank 70.82%; it then surged 114.99% in 2025.
• Tracing EDIT's Cash & Equivalents over 5 years: stood at $203.5 million in 2021, then tumbled by 30.46% to $141.5 million in 2022, then declined by 12.63% to $123.7 million in 2023, then climbed by 6.38% to $131.5 million in 2024, then climbed by 11.48% to $146.6 million in 2025.
• Per Business Quant, the three latest EDIT Cash & Equivalents figures stand at $146.6 million (Q4 2025), $165.6 million (Q3 2025), and $138.5 million (Q2 2025).

Peer Comparison